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Abstract: Currently, a global pandemic era of public health concerns is going on with the Coronavirus
Disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2). The first case of COVID-19 was reported from Wuhan’s Huanan seafood market in
China late December 2019. Bats, pangolins, and snakes have been nominated as salient carriers of
the virus. Thanks to its high pathogenicity, it can cause severe respiratory infections. Fever, dry
cough, sore throat, pneumonia, septic shock, and ground-glass opacities are the foremost clinical
manifestations of COVID-19. Immunocompromised patients are at high risk for COVID-19 infection
and may lead to death. Scientist and government agencies around the globe are putting forward
their best efforts and resources for the effective treatment of human coronavirus infections; however,
neither vaccines nor antiviral drugs are available for the treatment of human coronaviruses (HCoV)
infections such as SARS (severe acute respiratory syndrome), MERS (Middle Eastern respiratory
syndrome), and COVID-19. Since the outbreak, a plethora of research and review articles have been
published. Moreover, the mass media has bombarded the public with conflicting opinions about the
pandemic. There is a dire need for accurate and reliable information concerning this pandemic. In this
review, we have compiled the up to date information about the origins, evolution, epidemiology,
and pathogenesis of this disease. Moreover, very few reports have addressed the clinical features and
current status of treatment for COVID-19; we have adequately addressed these topics in detail in this
review. Finally, a detailed account of clinical trials of vaccines and other therapeutics currently in
progress has been delineated.
Keywords: COVID-19; cytokine storm; clinical features; dexamethasone; epidemiology; life cycle;
pathogenesis; RT-PCR; remdesivir; SARS-CoV-2; therapeutics; vaccines
1. Introduction
The recent pandemic has affected more than seventeen million people across 215 countries and
territories and caused deaths of more than 751.399 people as per reported data from John Hopkins
University Coronavirus Resource Center on August 13, 2020. World Health Organization declared
this pandemic a Public Health Emergency of International Concern (PHEIC) on 31 January 2020 [1].
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The novel coronavirus responsible for this pandemic was named “2019-nCoV” and was later changed
to “SARS-CoV-2” owing to its high similarity to severe acute respiratory syndrome coronavirus
(SARS-CoV) [2]. Finally, it became popular as Coronavirus Disease 2019 (COVID-19) [3]. Scientists and
governments around the globe are putting forward their best efforts and resources for the effective
treatment of human coronavirus (HCoV) infections. However, neither vaccines nor antiviral drugs
are approved for the treatment of HCoV infections such as SARS, MERS (Middle Eastern respiratory
syndrome), and the COVID-19 [4–7]. The word “corona” is derived from Latin, meaning crown,
as it possesses crown-like structure, hence called coronavirus. Coronaviruses possess a small size
of approximately 65–125 nm in diameter and hold the nucleic material as single-stranded RNA.
The similarity of the SARS-CoV-2 genome with SARS-CoV is about 79% [8]. SARS-CoV-2 is a type
of beta coronavirus [9], belonging to the Coronavirinae subfamily and Coronaviridae family in
order Nidovirales [10]. Alpha-, beta-, gamma-, and delta-coronaviruses are the subgroups of the
coronavirus family. The alpha- and beta-coronaviruses originated from mammals, while gamma- and
delta-coronaviruses originated from birds and pigs [11].
SARS-CoV and MERS-CoV originated from China in 2003 [12] and Saudi Arabia [13] in
2012, respectively, while the outbreak of COVID-19 began in December 2019 in Wuhan, China.
Coronaviruses (CoVs) have shown significant pathogenicity against humans and other vertebrates [14].
These coronaviruses are highly contagious [15] and can cause severe respiratory infection [16] and
acute respiratory distress syndrome (ARDS), followed by acute lung injury (ALI), leading to pulmonary
failure and, ultimately, death [17]. The current strain of COVID-19 is less deadly than the previous
MERS-CoV infection, with a mortality rate of 40%, and SARS-CoV, with a mortality rate of 10% [18,19].
Epidemiological investigations conducted by the World Health Organization (WHO) confirmed that
the COVID-19 triggered by the Huanan South China seafood marketplace in Wuhan. However, no
substantial evidence to exhibit that animal connection has been identified [20,21].
Further studies concluded that the genome sequence of COVID-19 is highly related to CoV infecting
bats [22]. Recently, it has been shown that bat CoVs can infect humans without an intermediate
carrier [23,24]. It is suggested that SARS-CoV-2 originated from the Chinese chrysanthemum bat
as their genomic sequence is very much similar to SARS-CoV-2. Furthermore, there may be an
intermediate host between humans and bats. The pangolin, an animal used by the Chinese for its
meat and having specific medicinal value, is thought to be the source of this virus. Epidemiologists
speculate that someone who purchased a pangolin from one of the wet markets in Wuhan got infected
after consumption, setting forward the chain of transmission [25].
A plethora of research and review papers have been published since the onset of this pandemic [7].
Moreover, the mass media is bombarding the public with conflicting information that is often misleading
and confusing. There is an urgent need for accurate and reliable information related to COVID-19.
In this review, we have tried our best to compile up to date and accurate information, citing reliable and
reputed journals, that will be helpful for the scientific community as well as the researchers working
in this field. First, we thoroughly explained the origins and evolution of SARS-CoV-2, followed by a
detailed account of its epidemiology and pathogenesis. There are very few reports that address the
comprehensive clinical features of the disease. Furthermore, information about treatment options for
COVID-19 is not adequate.
In this report, we have tried to gather the most updated and accurate data concerning this disease.
In addition, information about all ongoing clinical trials of vaccines and other potential therapeutics
has been addressed comprehensively. This review covers multiples aspects of COVID-19, including
the structure of the virus, evolution process of the disease, epidemiologic outcomes, pathogenetic data,
clinical features, diagnosis tools, treatment strategies, and prevention and control pathways.
2. Structure of SARS-CoV-2
The viral genome of SARS-CoV-2 is composed of 29,903 nucleotides and highly resembles
SARS-like CoVs infecting bats with a nucleotide similarity of 89.1%. SARS-CoV-2, like other CoVs,
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possesses a large RNA genome and exhibits a unique replication strategy. Specifically, the virus has a
nonsegmented positive-sense RNA genome with a 5′cap structure along with a 3′ poly (A) tail. This
unique structure allows the replicase polyproteins to read the genome for translation. Two-thirds
of the genome encodes nonstructural proteins (NSPs), while the remaining one-third encodes for
structural and accessory proteins. Vital structural proteins are spike (S), membrane (M), envelope (E),
and nucleocapsid (N) proteins. In addition, two viral replicase polyproteins termed PP1a and PP1ab
are produced by the virus, which are modified into 16 mature NSPs [26,27]. Figure 1 illustrates the life
cycle of the CoVs.
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Figure 1. The life cycle of a coronavirus, modified, and used from Zhang et al. [27] with an open-access
journal license. Upon entry to the host lungs, the CoV attaches to angiotensin-converting enzyme
(ACE-2) receptors and releases its nuclear content into the cytoplasm. Translation of the RNA makes
replicase complex, which results in the formation of transcripts of several proteins (named in pink
box). Translation of these transcripts makes spike (S), envelope (E), membrane (M), nucleocapsid (N),
and other accessory proteins. Assembly of these proteins produces a new virion that is matured and is
released out of the cell to infect other cells.
3. Evolution of COVID-19
It has been suggested that most of the coronavirus species infecting humans are found in the
bat reservoir [28]. Unsurprisingly, several scientist groups have certified the genetic resemblance
between SARS-CoV-2 and coronaviruses found in bats. A recent study showed that the gene sequence
of novel coronavirus has 96.2% similarity to the coronaviruses found in bat (RaTG13), 89.1% similarity
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to SARS-CoV [26], and about 50% similarity to MERS-CoV [29,30]. It has been documented that both
SARS-CoV-2 and SARS-CoV attach to the same receptor at the host named angiotensin-converting
enzyme (ACE2). After analyzing and evaluating 103 genomes of SARS-CoV-2 by single nucleotide
polymorphisms (SNPs), a recent study showed that the virus evolved into two L and S types. SNPs
showed absolute linkage across the strain of SARS-CoV-2. Examination of these types revealed that
the L-type (70%) is predominant as compared with the S-type (30%). The evolutionary inspection
suggested that the S-type is the most ancient form of SARS-CoV-2. Several tests and analyses also
showed that the L-type is more vigorous and cruel as compared with the S-type [31].
An unimaginably high degree of transmission raised a question of whether evolution was
stimulated by mutations. Genetic mutation analysis is essential for understanding evolution [32].
A study was conducted to understand and evaluate the genetic mutations pattern, in which eighty-six
genomes of SARS-CoV-2 were selected. All strains were identified in patients from Australia, China,
France, England, Germany, Taiwan, Japan, Belgium, USA, and Vietnam. China was used as a reference
to evaluate the sequence of the genome. SARS-CoV-2 presents a specific type of protein, a long
ORF1ab polyprotein at the 5′ end with additional structural proteins, including envelope protein, spike
glycoprotein, matrix, and nucleocapsid protein. The genetic examination identified three deletions in
the genomes collected from Australia, the USA, and Japan. Out of three deletions, two deletions were
noted in the ORF1ab polyprotein, and one deletion was noted in the 3′ end of the genome. Furthermore,
changing antigenicity may be driven by the mutations that occurred in the spike glycoproteins, which
may be the reason for the vigorous pathogenicity of SARS-CoV-2 [33].
Two precarious mutations were observed in the bat coronaviruses considered highly transmissible
so far and are attributed to the current COVID-19 pandemic. Out of the two, the first improved
the structure of spike proteins that appeared as projections on the outer surface of the virus. These
modified spike proteins allow the virus to attach to the ACE2 receptor, which spans the respiratory
tract lining. The second critical mutation permitted the virus to develop a protein dagger named
furin, which can slice other proteins to cause the virus to bind firmly to the lung and throat cells. It is
presumed that furin protein is the reason that COVID-19 is so deadly and contagious to humans [34].
Those mutations could have appeared while the virus was moving in bats. Another possibility of
mutation is that it could have occurred in a person who was infected by the former type of virus but
showed no sign and symptoms [35].
4. Epidemiology
As described earlier, SARS-CoV-2 originated from Wuhan, China, and has affected more than
20 million people across 212 countries and territories [14]. The transmission rate in some countries is
exceptionally high compared with others, and the number of infected patients is increasing gradually [36].
Chronologically, the first virus was obtained from a patient on 7 January 2020. In response, the sequence
of the viral genome was published by Chinese scientists on 10 January 2020, on Global Initiative on
Sharing All Influenza Data (GISAID) [37]. In China, five patients were admitted to the hospital between
18 and 29 December 2019, out of which one patient expired [38].
Additionally, 41 more patients were admitted to the hospitals by 2 January 2020. The diagnosis
of these patients confirmed COVID-19. Thailand was the first country that was infected after China,
and the first case was reported in Thailand on 13 January 2020, in a patient who traveled to Thailand.
Five hundred and seventy-one new cases of COVID-19 were reported by 22 January 2020, in 25 provinces
of China [39]. National Health Commission of China (NHC) confirmed the first 17 deaths due to
COVID-19 by 22 January 2020. On 25 January 2020, there were a total of 1975 infected patients in
China, out of which 56 expired [40]. According to another report from 30 January 2020, a total of
7734 cases were reported in China, and 90 cases were confirmed from other countries including
Vietnam, Nepal, Sri Lanka, Japan, Thailand, Republic of Korea, United States, United Arab Emirates,
Malaysia, The Philippines, India, Australia, Canada, Cambodia, Finland, Singapore, France, Germany,
and Taiwan [41].
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The Chinese Center for Disease Control and Prevention reported 44,672 confirmed cases by
11 February 2020, in which 81% of deaths were seen in patients age over 60 years. Mortality rates in
patients aged 70–79 and over 80 years were 8.0% and 14.8%, respectively [42,43]. On 28 February 2020,
WHO reported 82,000 confirmed cases worldwide, and the outbreak reached 45 countries other than
China. Following the rapid transmission course, 90,000 infected cases and 60 countries were dealing
with the COVID-19 outbreak by 2 March 2020. Previously, it was thought that children were less
susceptible to infection owing to a lack of evidence, but on 5 March 2020, Chinese studies concluded
that children are as susceptible as adults. By 13 March 2020, Europe was declared as the epicenter of the
outbreak by WHO. There were a greater number of reported cases in Europe as compared with the rest
of the world. In Europe, Italy was the largest outbreak territory. The United States President declared
the national emergency in the United States on 13 March 2020. By 27 March 2020, the total number of
infected patients reached half a million, and pandemic spanned about 175 countries. The one million
mark globally was reached on 2 April 2020. The next million cases were reported in less than two
weeks, and there were 2 million cases worldwide on 15 April 2020, with the United States being on
the top of the list, followed by Italy and Spain [44]. Currently, there are almost 21 million cases with
752,225 deaths around the globe, accessed on August 13, 2020 (https://coronavirus.jhu.edu/map.html).
Rapid transmission of COVID-19 reflects the high transmissibility and reproductive number (Ro).
Chinese reports show a Ro value of 2.2–2.7, meaning the infected cases double every 6–7 days [45].
The rate of transmission was inconceivably high, so several medical facilities were established,
and guidelines were reported by the CDC and the WHO to manage the escalating disease [46].
Another parameter for understanding the severity and prognosis of infection is the case fatality
ratio (CFR), which is calculated by dividing the number of expired patients by the total number of
diagnosed patients, multiplied by 100. According to the WHO situation report-185 of COVID-19,
the overall CFR was 5.12 as of 23 July 2020. A remarkable difference in CFR was noted in some
countries presented in Table 1. The exact cause for this variability is still a topic of investigation in the
scientific community. CFR is useful in estimating the risk of death within a population owing to a
specific disease. Data suggest increased mortality with advanced age has a well-known impact on the
prognosis of the disease. The median age of any population reflects the variation in fatality rates [47].
One of the Chinese reports revealed that the mortality rate could be 3% high in geriatrics, especially
over 80 [48].
Table 1. Case fatality ratio of Coronavirus Disease 2019 (COVID-19) in major countries of the world *.
CFR, case fatality ratio.
Territory Total Confirmed Cases Total Deaths CFR
France 167,456 30,060 17.95
Belgium 296,381 45,501 15.35
Italy 64,534 9808 15.19
United Kingdom 245,032 35,082 14.32
Netherlands 52,241 6139 11.75
Spain 267,551 28,426 10.62
Sweden 111,697 8862 7.93
Canada 78,504 5667 7.21
Ireland 25,819 1754 6.79
Brazil 86,361 4655 5.39
United States of America 281,413 14,853 5.28
China 33,796 1692 5.01
Switzerland 203,368 9101 4.47
Japan 2,159,654 81,487 3.77
Iran 27,029 990 3.66
Germany 3,868,453 141,479 3.65
Austria 20,038 711 3.55
Turkey 222,402 5545 2.49
Australia 12,896 128 0.99
Saudi Arabia 258,156 2601 1.00
Grand total 8,482,781 434,541 5.12
* World Health Organization (2020). COVID-19 Situation Report-185 (Accessed on 23 July 2020).
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5. Pathogenesis
SARS-CoV-2 targets the lower respiratory tract and causes mild to severe symptoms. COVID-19
patients show significant clinical symptoms, including non-productive cough, myalgia, reduced
leukocyte, dyspnea, fever, fatigue, and pneumonia. These symptoms are also shown by the patients
infected by SARS-CoV and MERS-CoV [49]. Although the pathogenesis of novel coronavirus disease
is not fully understood, the similarity of novel coronavirus with SARS-CoV can provide significant
information about the pathogenesis of COVID-19 infection. The body shows aggressive inflammatory
responses after viral entry, and it may cause severe damage to airways. The pathogenicity is increased
by a large number of viral copies replicated in the cell. The life cycle of SARS-CoV-2 is divided into
four stages: (i) entry of the virus, (ii) protein expression, (iii) transcription, and (iv) release of the virus
from the cell [50].
Coronavirus enters the cell by its sole determinant viral S-protein and undergoes several steps to
accomplish the replication. While S-protein is divided into two domains, S1 and S2 domain, the S1
domain is responsible for binding with the receptor, and the S2 domain accounts for the fusion of the
viral membrane with the cell membrane [51]. The viral spike glycoproteins attach themselves to the
ACE2 receptor of the cell, for both viruses SARS-CoV [52] and SARS-CoV-2 [53]. Initially, the virus
binds to the cell receptor and enters the cell through the process of membrane fusion of the virus
and plasma membrane [54]. Belouzard et al. [55] showed that the proteolytic processes occur in the
S2 domain, which accounts for fusion and infection. After the viral entry, the RNA genome of the
virus is released in the cytoplasm and then undergoes translation, followed by transcription, through
which the virus continues to replicate [56]. After the formation of viral proteins by translation, these
new proteins are inserted into the endoplasmic reticulum or Golgi apparatus. When viral RNA is
combined with the proteins, the nucleocapsid is formed. Finally, the newly formed viruses enclosed in
the vesicles are released by exocytosis [56]. The viral release marks the time when infected patients
start displaying significant symptoms and laboratory values. Higher leukocyte count, respiratory
problems, and exaggerated pro-inflammatory cytokines are exhibited by COVID-19 patients. In a case
report, a patient presented with fever for the past two days displayed abnormal breathing sounds and
a temperature of 39.0 ◦C. The real time-polymerase chain reaction (RT-PCR) conducted on the sputum
culture showed a positive result for COVID-19 and confirmed the disease [57].
The laboratory analysis showed a leukocyte count of 2.91 × 109 cells/L, of which neutrophils were
70%. Further, the C-reactive protein was 16.16 mg/L (normal range = 0–10 mg/L). The erythrocyte
sedimentation rate (ESR) was also high with D-dimer. The primary pathogenesis of the nCoV is
associated with respiratory infections, pneumonia, ground-glass opacities (GGOs), acute cardiac injury,
ARDS, and RNAaemia [38]. Additionally, high blood values of chemokines and cytokines were also
observed in patients, including IL1-β, IL7, IL8, IL9, IL10, IL1RA basic FGF2, GMCSF, IFNγ, IP10, GCSF
MCP1, MIP1α, MIP1β, PDGFB, and TNFα, as shown in Figure 2. Critical patients showed a high value
of pro-inflammatory cytokines as a cytokine storm, including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1α,
GCSF, and TNFα, which exaggerated the severity of the infection [58]. This exaggerated immune
response destroys the lung’s infrastructure [59].
Current models give information about the three stages of the immune response. The first stage
involves the early activation and persuasive interferon response for clearing the virus. The second
stage exhibits the delayed response of interferon that may lead to tissue damage. The third stage
leads to hyper-inflammation, followed by exaggerated macrophage activation, resulting in fibrosis
dysregulation of tissue repair processes [59]. For each step, potential therapeutic options can be
developed. Some are under clinical trials to evaluate their efficacy along with safety. Initially, the virus
attaches to the ACE2 receptor. TMPRSS2 is responsible for the viral protein cleavage. Protease
inhibitors can be designed and developed to prevent spike protein cleavage. Blocking the viral fusion
through either TMPRSS2 or receptor ACE2 can prevent the infection. For removing pro-inflammatory
cytokines, several novel models have been proposed in which the blood of a COVID-19 patient is passed
through customized columns that recognize and trap the pro-inflammatory cytokines, and then the
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purified blood is administered back to the patient [60]. ARDS seen in several COVID-19 patients may
lead to secondary infections, and respiratory failure leads to death in 79% of critical cases. Furthermore,
the cytokine storm may lead to sepsis and cause death in 28% of critical cases [61]. Scientists are trying
to design therapeutics to prevent this exaggerated immune response responsible for the enhanced
severity of the infection [60,62].
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Figure 2. Inflammatory responses during severe acute respiratory syndrome coronavirus (SARS-CoV-2)
infection. SARS-CoV-2 attaches to the ACE2 receptor, and the spike protein is cleaved by the type II
transmembrane serine protease (TMPRSS2), resulting in viral replication. Mature viruses are released
from the cell by exocytosis. In the dysfunctional immune response, cells may undergo pyroptosis and
release adenosine triphosphate (ATP), nucleic acids, and ASC oligomer. These impaired-associated
molecular forms can be detected by the neighboring epithelial cells and other alveolar macrophages.
In response, th pro-inflammatory cytokines r released along with chemokines, including IL-6, IP-10,
macrop age inflammatory protein 1α (MIP1β), MCP1, a MIP1α. These released proteins draw the
monocytes, T cells, and lymphocytes to the inflammatory site, causing exaggerated inflammation at the
site of action. This exaggerated response damages the lung’s infrastructure. This cytokine storm can
move to other organs and may damages the other organs as well.
As discussed earlier, ACE2 is the receptor for SARS-CoV-2. It has been reported that the
involvement of ACE2 receptors is also related to the renin–angiotensin system (RAS) in 2019-nCoV
pathogenesis [63]. Very recently, a meta-analysis was conducted to get insight into the relationship
between the prevalence of COVID-19 disease and the genetic differences in the genes involved in the
RAS syst m [63]. The res lts of the study suggest that the in rease f the I/D allele frequency ratio
significantly incr ases the recovery rate (point estimate: 0.48, confidence interval (CI) 95%: 0.05–0.91,
p = 0.027), but the I/D allele frequency ratio has no significant difference in the case of death rate (point
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estimate: 1.74, CI 95%: 4.5–1.04, p = 0.22). The I/D allele ratio of ACE receptors varies significantly
across world regions, accounting for the different recovery rates across regions, but it also raises
concerns that ethnic and genetic differences can impact the effectiveness of currently investigated
RAS-associated medications in different regions [63].
6. Clinical Features
SARS-CoV-2 represents an incubation period of 6.4 days, fluctuating between 2.1 and 11.1 days
with possible asymptomatic transmission [64]. Infection is manifested after the incubation period.
The period from the commencement of disease leading to death fluctuates between 6 and 41 days with
an average of 14 days. The age of patient and condition of the immune system are the sole determinants
of this period. Persons with a weaker immune system are more susceptible to infection. This period is
shorter in geriatrics >60 years, as older patients have a weaker immune system [65]. The most common
symptoms of COVID-19 are dry cough, myalgia, diarrhea, headache, and high-grade fever [66]; fever
is reported in more than 90% of cases, cough in 75%, and dyspnea in 50% of the patients [8]. Fewer
patients may also develop kidney damage, ARDS, septic shock, and acute cardiac injury requiring
hospitalization [67]. The clinical symptoms are presented in Table 2.
Table 2. Clinical symptoms integrated with the severity of COVID-19 [48,66].
Clinical Type Symptoms
Mild disease No signs of pneumonia; it happened in 81% of patients.
Severe disease
Oxygen saturation of blood ≤93%, infiltration of lungs ≥50% within one or two days.
The ratio of PaO2/FiO2 (oxygen partial pressure/fraction of inspired oxygen) <300.
GGO (ground glass opacities): 14% of cases acquired severe symptoms.
Critical disease Failure of the respiratory system, septic shock, concerted organ dysfunction, or multipleorgan failure (MOF); it happened in 5% of patients.
Mutual laboratory findings include lymphopenia and leucopenia. These findings were common
and observed in a large number of cases [68]. Chest computed tomography (CT) scan showed
clinical features including pneumonia and other abnormal features, for instance, RNAaemia, acute
cardiac injury, and occurrence of GGO, that set the path towards death. In several cases, multiple
marginal GGOs were observed in both lungs, which expectedly triggers the systemic and localized
immune reaction, causing severe inflammation [65]. Atypical CT scan showed single, multiple solid,
and consolidated nodules in the middle of the lobe of right or left or both lungs, fenced by GGOs in the
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Figure 3. Atypical CT imaging of a 56-year-old female presented with a history of 3 days of persistent
fever. Laboratory findings: reduced total protein level (54.0 g/L), reduced albumin value (35.5 g/L),
low value of globulin (18.5 g/L), white blood cells (WBCs) (4.87 × 109/L), lymphocytes (0.49 × 109/ L),
and decreased level of eosinophil (0 × 109/L). Imaging inspection: (A) A lateral section of the center
of right lung lobe covered GGO. (B) Patchy GGO in the upper part of the right lung with sporadic
consolidated lesions. (C) GGO in both lungs with sporadic consolidation lesions. (D) Uneven GGO
in the middle and dorsal section of the right lung. Adopted from Kui et al. through open-access
license [69].
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Although there are some similarities, the symptoms manifested by earlier coronaviruses are not
precisely similar to those of COVID-19. For instance, the distinctive features of COVID-19 are fever,
fatigue, and dry cough. In contrast, upper respiratory tract symptoms like rhinorrhea, sore throat,
and sneezing are uncommon, which were commonly observed in previous coronavirus infections.
Moreover, COVID-19 patients present with intestinal symptoms like diarrhea, which were less prevalent
in MERS-CoV and SARS-CoV infections [70].
In addition, patients may also report anosmia and dysgeusia as early symptoms of COVID-19 [71].
Anosmia (loss of sense of smell) and dysgeusia (alteration of the sense of taste) are also associated with
COVID-19 patients. The American Academy of Otolaryngology-Head and Neck Surgery developed the
COVID-19 Anosmia Reporting Tool for clinicians to conduct a pilot study. This tool allows clinicians to
submit the anosmia and dysgeusia associated COVID-19 patients. They analyzed the first 237 entries
and revealed that anosmia was observed in 73% of patients prior to the diagnosis of COVID-19 and was
the early symptom in 26.6% of COVID-19 patients. Conclusively, this study suggested that anosmia
can be the representative symptom of COVID-19 [72,73].
7. Diagnosis
The diagnosis and treatment program for COVID-19 was formulated by NHC of China [69,74]
and was previously suggested by WHO for SARS and MERS [75–78]. The specific diagnostic measures
have been implemented for suspected as well as confirmed cases: a patient with a minimum of two
clinical symptoms and at least one exposure history is accounted as a suspected case. The suspected
case should show at least three clinical symptoms if there is not any clear exposure history.
The serology testing for COVID-19 is helpful and provides the basis for diagnosis. In the case of
the unavailability of molecular testing, the serological test provides a means to triage the suspected
cases of COVID-19. A fast-serological test with specific performance features is highly important to
avoid missing factual cases of COVID-19. A positive test for IgM or IgG antibody strongly indicates
SARS-CoV-2 infection. This approach is extremely effective in individuals 5–10 days after the onset of
symptoms [79]. IgG or IgM positive patients are quarantined, and those who need critical care are
referred to the hospital. Those with a negative serological antibody test have a swab collected for
molecular testing. The experience in China has shown that the use of a serological antibody test can
improve the sensitivity of COVID-19 case detection [80]. This approach allowed to test a huge number
of symptomatic individuals rapidly in the community, minimizing the waiting time for molecular
testing and preventing the health-management system from being overwhelmed [79].
Subsequently, when nucleic acids of SARS-CoV-2 by RT-PCR results come back positive, it is
accounted for as a confirmed case [76]. Meanwhile, a CT scan of the chest provides confirmed diagnostic
evidence of COVID-19 disease as it has greater sensitivity and high specificity. Thus, the chest CT has
been recognized as a significant indicator for COVID-19 diagnosis in different epidemic areas [15,31,81].
It can be said that the chest CT is an essential procedure for the timely detection and management
of this infection. However, it should be noted that a patient with an RT-PCR may have a negative
chest CT at the time of admission [82]. In this context, a study compared three RT-PCR analyses,
targeting the RNA-dependent RNA polymerase RdRp/Helicase, spike, and nucleocapsid genes of the
virus with testified RdRp-P2 assay, which is extensively used in more than 30 European countries.
According to this study, RdRp/Hel is more specific and gives accurate results for SARS-CoV-2. Moreover,
the RdRp/helicase assay of COVID-19 does not cross-react with other types of coronaviruses and
respiratory microorganisms in the cellular medium. In contrast, the RdRp-P2 assay, reported for
previous coronaviruses, reacts with the pathogens of the respiratory tract in the cell culture. Thus,
the COVID-19-RdRp/Hel can be considered sensitive and specific, and this information helps fortify
the diagnosis of COVID-19 [83].
Laboratory findings can be helpful in predicting COVID-19 cases with positive RT-PCR. ALT,
C-reactive protein, neutrophils, AST, and lymphocytes counts have very good accuracy in predicting
cases with positive RT-PCR for COVID-19 patients [84]. A study suggested that the number and
Int. J. Environ. Res. Public Health 2020, 17, 5904 10 of 22
percentage of white blood cells (WBCs), lymphocytes, and neutrophils were significantly different
between positive and negative RT-PCR cases for COVID-19 patients [85]. Another cohort study
suggested that lymphopenia (low levels of lymphocytes) occurred in 80% of COVID-19 patients [86].
An increased level of AST and ALT was also noted in severely affected patients [87]. High levels of
LDH, C-reactive protein, neutrophils, and erythrocyte sedimentation rate (ESR) were also notable in
COVID-19 patients [88]. Thus, these laboratory findings have great importance in terms of predicting
COVID-19 cases with positive RT-PCR [84].
8. Treatment
Currently, no specific and sensitive therapeutic regimen is available for the treatment of COVID-19.
However, the primary step is isolation to prevent any type of contact that later may cause transmission
of the disease. If the patient experiences any mild symptoms, it should be managed at their residence
with proper counseling to patients about the critical signs and symptoms. The primary management
protocols include the management of cough and fever [89]. First-line therapy to manage the fever
is acetaminophen, while expectorants such as guaifenesin are used for non-productive cough [90].
Patients with SARS, hypoxemia, respiratory distress or shock should be treated by the administration
of instant oxygen therapy. The frequency of oxygen therapy should be 5 L/min to obtain SpO2 of
≥92–95% in pregnant women, and ≥90% in adults and children [91]. Antiviral therapy is also being
tried to manage the infection [92].
Critical patients show an unhealthy immune response that eventually causes hyper-inflammation.
This exaggerated immune response should be controlled and checked by different approaches and
procedures. As discussed earlier, inflammatory cytokines are released at the site of infection and cause
infiltration of lungs. Clinical trials are underway to identify the benefits of blocking cytokine storm
targeting IL-1β and IL-6, as shown in Table 3.
Table 3. Potential therapeutic targets associated with macrophage activation under clinical trials [93–95].
Drug Name Drug Type Target Role of Target Clinical TrialNumber
Tocilizumab Anti-IL-6 receptor IL-6 signaling process Pro-inflammatory
NCT04306705;
NCT04346355;
NCT04320615;
NCT04317092;
NCT04335071;
a NCT04331808
No drug approved Various TLR4–TRIF signaling Pro-inflammatory NA
Emapalumab Anti-IFNγ IFNγ Pro-inflammatory NCT04324021
Tofacitinib JAK1/JAK3inhibitor JAK-STAT signaling
Pathway mediates
cytokine signaling
a NCT04340232;
a NCT04320277
Cenicriviroc
(not approved)
CCR2 and CCR5
antagonist CCR2
Promotes monocyte
recruitment in tissues
Clinical trial in
progress
Sargramostim GM-CSF GM-CSF signaling Pro- inflammatory;repairing lung tissues NCT04326920
Fliximab; adalimumab;
golimumab Anti-TNF TNF signaling Pro- inflammatory NA
Anakinra IL-1 receptorantagonist IL-1β signaling Pro-inflammatory
NCT04339712;
NCT04324021;
NCT04330638;
a NCT04341584
Data from ClinicalTrials.gov. IFNγ, interferon-γ; JAK, Janus kinase; CCR2, CC chemokine receptor 2; CCR5, CC
chemokine receptor 5; STAT, signal transducer and activator of transcription; GM-CSF, granulocyte-macrophage
colony-stimulating factor; NA, not applicable; TLR, Toll-like receptor; a clinical trials not yet recruiting at time
of publication.
Interfering cytokine storm signaling can prevent hyper-inflammation, thereby reducing infection.
Current evidence shows that the overproduction of macrophages linked to monocytes accumulates in
tissue that can cause lung infiltration. For instance, it is found that CCR2 activation contributes to the
accumulation of monocytes in the tissue, causing severe inflammation. So monocytes’ accumulation
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can be reduced by blocking the CCR2, resulting in minimizing hyper-inflammation [96]. Different
clinical trials are underway to reduce the hyper-inflammation by JAK inhibitors [97]. Other relevant
clinical trials are ongoing to evaluate the blocking of myeloid-derived cytokines, for example, TNF [98]
and GM–CSF. By targeting this cytokine signaling, the hyper-inflammation can be reduced [99].
Remdesivir is a broad-spectrum antiviral prodrug, which is a nucleotide analog and is metabolized
in the cell to adenosine triphosphate analog, which inhibits the viral RNA polymerases. Remdesivir
is the drug of choice against several viral families, including Ebola, SARS-CoV, and MERS-CoV.
Remdesivir is being used for prophylactic and therapeutic purposes and has shown remarkable efficacy
in the non-clinical model of coronaviruses [100,101]. It has also shown promising activity against
SARS-CoV-2 [102,103]. A large clinical trial of remdesivir is currently underway for patients with
mild to moderate symptoms [104]. The critically ill patients treated with amicable use of remdesivir
showed better efficacy, and the clinical condition of the patients was improved [105]. On 1 May 2020,
the Food and Drug Administration (FDA) of the USA authorized the emergency use of remdesivir for
the treatment of COVID-19 [106]. The recent version of treatment guidelines by NHC recommends
the use of lopinavir/ritonavir and IFN-α. The first version of treatment guidelines was issued on
15 January 2020, later revised five times, and the 6th edition is the most recent one that was issued on
18 February 2020. Lopinavir/ritonavir, ribavirin, and IFN-α were added in the 5th edition of treatment
guidelines for combating COVID-19. Later, arbidol and chloroquine phosphate have also been added
in the 6th edition, as these drugs show better clinical efficacy. Potential drugs included in the 6th
edition of treatment guidelines by NHC of China, as shown in Table 4, presented promising therapeutic
effects [107]. Although the recent study was an open-label, individually randomized, controlled trial
representing patients admitted in hospitals, treated with lopinavir/ritonavir (400 mg/100 mg), no
clinical improvement was observed by this treatment beyond standard care [108]. On the basis of the
guidelines, ritonavir is used as a booster to enhance the efficacy of lopinavir. These medications are
prescribed to be taken for a short period of time (<2 weeks), suggesting their acute response.
Table 4. Antivirals included in the treatment guidelines issued by NHC of China for COVID-19,
version 6 [107,109]. NHC, National Health Commission; t.i.d, three times a day; b.i.d, two times a day.
Drug Regimen Dosage Route ofAdministration
Length of
Therapy
Ribavirin 500 mg, t.i.d, combination therapywith lopinavir/ritonavir IV infusion ≤10 days
Chloroquine phosphate 500 mg one time, b.i.d Orally ≤10 days
Arbidol 200 mg, one time, t.i.d Orally ≤10 days
Lopinavir/ritonavir 200 mg/50 mg, dosage form:capsule, two capsules one time, b.i.d Orally ≤10 days
IFN-α 5 million U dose one time, b.i.d Vapor inhalation ≤10 days
Hydroxychloroquine, lopinavir/ritonavir, chloroquine, and darunavir/cobicistat are being used
for patients with severe conditions. Interferon-beta B1 is extensively used for critical patients [110].
Another drug, oseltamivir, is being used in China by the medical personnel for suspected patients,
but there is a lack of evidence on the specific activity of oseltamivir against COVID-19. A 54-year-old
female patient from Wuhan city presented with fever for the past two days. Two tests were conducted,
the first test was not positive, but the second test confirmed the disease. Meanwhile, this woman was
treated with oseltamivir for three days, and her chest CT indicated reminiscent improvement in the
density of GGO [90].
Patients with vigorous immune reactions can be treated with glucocorticoids such as
methylprednisolone, which is used at 1–2 mg/kg/day dose in children and 25–150 mg/day in adults.
It is believed to reduce the prognosis of the disease in patients with impaired oxygen index, that is,
less than 300 mm Hg, limited to 5 days [69]. For patients with premature disease stage, without
hypoxia, use of corticosteroids should be avoided. However, in critical situations where mechanical
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ventilation is mandatory, anti-inflammatory therapy is possibly useful and can be employed [59].
A glucocorticoids-based drug dexamethasone may be employed against COVID-19. Dexamethasone
is a synthetic corticosteroid approved by the FDA in 1958 as a broad-spectrum immunosuppressor,
which is about 30 times as active as cortisone and possesses a longer duration of action (2–3 days).
Dexamethasone may not only limit the production and damaging effect of the cytokines, but
may also inhibit the protective function of T cells and reduce the ability of B cells to synthesize
antibodies [111]. Dexamethasone may be a useful agent for short-term therapy in severe intubated
COVID-19 patients [112]. A recent controlled open-label, randomized trial of dexamethasone in
hospitalized patients, concluded that the use of dexamethasone with the aid of mechanical ventilation
or oxygen alone resulted in lower mortality at the dose of 6 mg once daily for 10 days. However,
dexamethasone was not effective in those patients who were not receiving respiratory support [113].
Dexamethasone is on an essential medicines list recommended by the World Health Organization and
is readily accessible worldwide at a low cost. Guidelines issued by the U.K.’s chief medical officers
and by the National Institutes of Health in the United States have already been updated to recommend
the use of glucocorticoids such as dexamethasone in hospitalized patients with COVID-19 [114,115].
As discussed earlier, a variety of drugs are recommended and tested in non-clinical models;
among them, penciclovir, ribavirin, and favipiravir require high doses to decrease the infection and are
supposed to be less effective [90]. Chloroquine and its derivative hydroxychloroquine are considered
to be effective against COVID-19 and are currently used in Chinese patients to reduce viral infection.
Potential drug therapy for COVID-19 is listed in Table 4 to gain a better understanding of treatment [116].
An open-label, non-randomized clinical trial showed that hydroxychloroquine (600 mg/day) treatment
is magnificently related to a decreased rate of viral replication in patients, and its effectiveness is
reinforced by azithromycin (500 mg/day) [116]. Hydroxychloroquine showed superior sensitivity over
chloroquine against COVID-19 [117]. Contrary to the previous results, at the time of publication, an
open-label, randomized controlled clinical trial showed that the use of hydroxychloroquine alone or
with azithromycin did not improve the clinical status of hospitalized patients with mild to moderate
COVID-19 as compared with standard care [118].
According to many reports, the COVID-19 patients are at high risk for venous thromboembolism,
a term that associates deep vein thrombosis (DVT) [119]. In this context, patients are treated
prophylactically by giving low molecular weight heparin (LMWH), when multiple risk factors exist.
Hence, hospitalized COVID-19 patients are generally treated with higher doses of LMWH than
recommended for thromboprophylaxis [120]. A recent document by the Italian Drug Agency (AIFA)
suggested the use of 80 to 100 mg enoxaparin daily, instead of the usual 40 mg, while in some hospitals,
even higher, up to full anticoagulant doses of LMWH or unfractionated heparin are used [121].
SARS-CoV-2 targets the ACE2 receptor via spike-like protein, so it is an efficient target for the
drugs, including chloroquine, promazine, and emodine, to prevent the viral attachment with the
surface of the host cell [122]. S protein priming is the next precarious phase of viral entry into the
host cell, where it is required to be cleaved by intracellular proteases including TMPRSS2, cathepsins,
and furin for the fusion of viral membrane with the cell membrane of the host. S-protein priming by
TMPRSS2 is the most crucial phase for the prognosis of infection into the host, so the viral infection
can be controlled with the use of protease inhibitors, including camostat and nafamostat, which
target TMPRSS2, and thereby inhibit the viral fusion [123]. The immune system represents the
defensive mechanism in attacking the virus; major immune cells include T-lymphocytes and natural
killer cells [122]. Apart from antiviral therapy, the use of antibiotics can be used for the associated
co-infections, community-acquired, or hospital-acquired pneumonia, and it depends on the clinical
results of the patients. These broad-spectrum antibiotics, including azithromycin and fluoroquinolones,
can be given as empirical therapy to cover all attainable pathogens, continuing the therapy until
all pathogenic bacteria are cleared from the body. The combination therapy of azithromycin with
hydroxychloroquine showed significant activity against COVID-19 infection [124]. Table 5 delineates
the potential therapeutics against COVID-19.
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Table 5. Potential therapeutics against SARS-CoV-2 (COVID-19) [68,105,112,116,125–130]. IFNs, interferons.
Drug Type Mechanism Recommendation
Remdesivir Antiviral Remdesivir targets the viral RNA polymerases to inhibit thereplication of the virus, previously used for Ebola
Clinical trials have been
conducted
Favipiravir Antiviral Favipiravir interacts with viral RNA polymerase, thusinhibiting viral replication Efficacy has been proven
Convalescent plasma Antiviral Convalescent plasma obtained from the cured ones providesprotective antibodies against SARS-CoV-2
Clinical trials have been
conducted
Chloroquine
Hydroxychloroquine Anti-malaria
Inhibition of endosomal acidified fusion and also have an
anti-inflammatory effect Efficacy has been proven
IFNs Immuno-enhancer IFNs interfere with the viral RNA transcription andtranslation of protein, and thus inhibit viral replication
Clinical trials have been
conducted, and efficacy
has been proven
Lopinavir/ritonavir Antiviral It inhibits the protease enzyme, thereby preventing thecleavage of polyproteins, and it produces immature particles. Clinical trials underway
Corticosteroids Corticosteroids Corticosteroids diminish pro-inflammatory cytokines andshow an anti-fibrotic property Controversial state
Dexamethasone Glucocorticoids
Dexamethasone inhibits the protective function of T cells and
reduces the ability of B cells to synthesize antibodies, as well
as limits the damaging effects of cytokines
Clinical trials underway
Vitamin C
Nutritional
supportive
management
Vitamin C strengthens the immunity response by increasing
IFN production and enhancing the capability of phagocytosis
by neutrophils
Clinical trials have been
conducted
Zinc
Nutritional
supportive
management
Zinc is mandatory for the efficient activity of the immune
system and also has antiviral property, as it also enhances the
therapeutic activity of hydroxychloroquine
Clinical trials have been
conducted
Enoxaparin
Low molecular
weight heparin
(LMWH),
anticoagulant
Enoxaparin showed its anticoagulant activity and is used in
thromboprophylaxis in COVID-19 patients Clinical trials underway
Some researchers recommend the use of vitamin C supplements that may help to treat the clinical
symptoms of the patient by potentially activating the immune system. These supplements help to
reduce the severity of pneumonia; however, this requires more clinical evaluation [131]. Supplements
of vitamin D3 can also be useful for combating the infection. While vitamin D can activate the innate
immune system, its decreased value indicates enhanced autoimmunity and susceptibility towards
infection. Grant et al. indicated the use of vitamin D in decreasing the probability of respiratory
infections caused by COVID-19. As vitamin D induces the antimicrobial peptides such as defensins
and cathelicidins that eventually interfere with the viral growth and pro-inflammatory cytokines, more
evaluation is needed by randomized controlled trials on a large number of individuals to reach to a
conclusion [132].
Presently, no vaccine exists against COVID-19; however, several clinical trials are underway,
as discussed in Table 6. Scientific research is ongoing by various medical institutes and companies to
produce effective vaccines all over the world that can combat COVID-19.
A most recent study published in Lancet claims the production of a vaccine named PittCoVacc
developed by the University of Pittsburgh School of Medicine. PittCoVacc uses S-protein, which
provides protection by the induction of specific antibodies in the body. Researchers are conducting
different analyses on the vaccine, and they are planning a series of tests in humans in the coming
months [129]. Another vaccine named mRNA-1273 is being developed by the National Institute of
Allergy and Infectious Disease researchers combined with biotechnology institution Moderna. In this
case, mRNA is enclosed in lipid nanoparticles that encode the S-protein of the virus, and then it
takes the antigen into the body. In response to antigen, specific antibodies are produced that provide
protection against SARS-CoV-2. The clinical trial of the mRNA vaccine is underway, while scientists
are working together to evaluate the pathogenesis and clinical features for combating the disease by
approaching a series of therapeutic options and development of other vaccines [133].
University of Oxford, United Kingdom, conducted a randomized clinical trial of the COVID-19
vaccine named ChAdOx1 nCoV-19 vaccine. The estimated participants in this study were about 10,260,
and this vaccine was administered intramuscularly. Fortunately, this vaccine appeared to be most
effective in participants showing an effective response and has already entered into second and third
clinical trials (clinicaltrials.gov).
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Finally, there is an emerging concern that patients recovering from COVID-19 may be at risk of
reinfection. To address this concern, Bao et al. investigated acquired immunity to SARS-CoV-2 in
rhesus macaques. This study published recently suggests that immunity acquired following primary
infection with SARS-CoV-2 may protect upon subsequent exposure to the virus [134]. However, more
studies are needed to reach a definitive conclusion.
Table 6. Development of vaccines for COVID-19 that are under clinical trials.
Vaccine Allocation Title of Study Location Clinical TrialNumber
BCG vaccine Randomized
Reducing Health Care Workers
Absenteeism in Covid-19 Pandemic
Through BCG Vaccine
(BCG-CORONA)
Multiple sites in the
Netherlands NCT04328441
SARS-CoV-2
inactivated vaccine Randomized
A Randomized, Double-Blinded,
Placebo-Controlled, Phase I/II Clinical
Trial, to Evaluate the Safety and
Immunogenicity of the SARS-CoV-2
Inactivated Vaccine in Healthy Adults
Suining County
Center for Disease
Control and
Prevention in China
NCT04352608
mRNA-1273 Non-Randomized
Safety and Immunogenicity Study of
2019-nCoV Vaccine (mRNA-1273) for
Prophylaxis of SARS-CoV-2 Infection
(COVID-19)
Multiple sites in
America NCT04283461
LV-SMENP-DC
vaccine and
antigen-specific
CTLs
NA
Phase I/II Multicenter Trial of
Lentiviral Minigene Vaccine
(LV-SMENP) of Covid-19 Coronavirus
Shenzhen
Geno-immune
Medical Institute
Shenzhen,
Guangdong, China
NCT04276896
bacTRL-Spike
vaccine Randomized
A Phase 1, Randomized,
Observer-Blind, Placebo-Controlled
Trial to Evaluate the Safety,
Tolerability, and Immunogenicity of
the bacTRL-Spike Oral Candidate
Vaccine for the Prevention of
COVID-19 in Healthy Adults
Canadian Center for
Vaccinology
Dalhousie University,
IWK Health Centre
a NCT04334980
ChAdOx1 nCoV-19
vaccine Randomized
Phase 2/3 Study to Determine the
Efficacy, Safety and Immunogenicity
of the Candidate Coronavirus Disease
(COVID-19) Vaccine ChAdOx1
nCoV-19 vaccine
Multiple sites in
United Kingdom NCT04400838
Inactivated
SARS-CoV-2
Vaccine
Randomized
A Randomized, Double-blind,
Placebo-controlled, Phase Ia/IIa Trial
of an Inactivated SARS-CoV-2 vaccine
in Healthy People Aged 18 to 59 Years
Multiple sites in
China NCT04412538
BCG, Bacillus Calmette–Guérin; a clinical trials not yet recruiting at the time of publication; data from clinical
trials.gov.
9. Prevention and Control
Several methods have been implemented based on actual infection control and segregation to
control the transmission of COVID-19. WHO and CDC published guidelines for the prevention and
control of the infection. For instance, individuals should wash their hands with alcohol-based sanitizers
on a routine basis. Touching of nose, mouth, and eyes should be avoided as they are the critical part for
holding the infection. Moreover, a distance of approximately of 1 m from those who are sneezing and
coughing should be maintained. People should uphold respiratory hygiene, such as covering nose and
mouth during coughing. Individuals should wear a mask while meeting with other persons or going
outside. Individuals are supposed to sanitize their workplaces [135]. Medical teams are supposed to
cover their nose and mouth by licensed N95 masks. In some areas, the availability of the N95 mask
is limited; in this case, the use of surgical masks while treating suspected and confirmed patients
should be ensured. Proper use and disposal of the surgical mask is necessary to minimize the risk of
transmission [136,137]. As there are clinical trials of vaccines underway, for now, the most effective
prevention for the entire population is to minimize the exposure to the virus. Center for Disease Control,
USA, WHO, and the Chinese CDC have provided proper guidelines to enhance awareness among
the population about the prevention of COVID-19. The main emphasis of the guidelines includes
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awareness on how to wear a face mask, appropriate hand washing techniques, preventive measures
at home and workplaces, and disinfection procedures and protocols. Furthermore, the guidelines
are available on the treatment, prevention, and control of COVID-19. The guidelines also endorse
ways of minimizing the fear of COVID-19 among the overall population [138]. Considering all the
nonpharmaceutical measures assist the maintenance of the public outcomes of the pandemic to be in
control, because of several financial reasons, the numbers are again elevating. There are multiple steps
involved in preparation for personal protection equipment (PPE), including identifying PPE and to
ensure a proper gown size, performing hand hygiene using hand sanitizer, wearing proper masks, put
on face shield or goggles, and gloves in areas that could be necessary. The guidelines could be different
based on the profession, location, and severity of the disease.
10. Conclusions
This review provides insight into various aspects of COVID-19, including disease pathophysiology,
its clinical representation, mechanism of drugs actions, and impacted population. However, the major
concentration of this report was to emphasize potential therapeutics and provide all essential information
related to it in one document. On the basis of the class of drugs, multiple classes of drugs have been
shown to work primarily to stabilize the patient and, secondly, target the virus for treatment.
The first class of drugs is anti-inflammatory ones that deal with cytokines signaling through targeting
various receptors such as IL-6. The major outcome of the treatment is to reduce the inflammation during
the therapy. The second group of medications is classic orally administered drugs that have been used
for antiviral or anti-parasite ones such as chloroquine phosphate and lopinavir/ritonavir. Among them,
remdesivir has been approved by FDA for the emergency room treatment of COVID-19, suggesting its
promising potency. In addition to all the mentioned medications, corticosteroids are used to assist
with reducing the pro-inflammatory effect. However, owing to their unfavorable side effect profile,
their use should be limited to a short period of time in critical patients.
It needs to be emphasized that, among all tested drugs, antiviral compounds such as remdesivir
inhibit RNA transcription, leading to reduced viral load. This class of drugs is potentially the most
promising tool with which to treat COVID-19 patients. Thus, although there is no solid evidence
available to prove their long-term clinical outcomes as of this day, drugs targeting viral RNA are the
most promising tools in this battle. Further investigations are required to test a library of synthesized
antiviral agents to obtain the most potent candidate to be used in clinics. The ongoing trials of the
vaccine will be a hope to provide a vaccine displaying efficacy without side effects to overcome the
COVID-19 pandemic to humankind.
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